Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug
12:58pm, Sunday, 07'th Dec 2025
The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs.
Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
09:30am, Sunday, 07'th Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with MF Presented at ASH 2
Incyte: Buy At This Inflection Point
09:00am, Saturday, 06'th Dec 2025
Incyte Corporation's rapid non-Jakafi portfolio growth and strong operating leverage look decent amid still-cheap valuation, supporting attractive risk-reward over the coming quarters ahead. Q3 revenu
Incyte Corporation $INCY Shares Bought by Fisher Asset Management LLC
04:08am, Saturday, 06'th Dec 2025
Fisher Asset Management LLC boosted its stake in shares of Incyte Corporation (NASDAQ: INCY) by 74.6% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 29,
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of “Hold” from Brokerages
01:57am, Thursday, 04'th Dec 2025
Shares of Incyte Corporation (NASDAQ: INCY - Get Free Report) have received an average rating of "Hold" from the nineteen brokerages that are covering the firm, Marketbeat Ratings reports. One analyst
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 03'rd Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript
03:13pm, Wednesday, 03'rd Dec 2025
Incyte Corporation (INCY) Presents at Evercore 8th Annual Healthcare Conference Transcript
Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo
08:00am, Wednesday, 03'rd Dec 2025
MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) commends the newly announced partnership between Incyte and supermodel and beauty entrepreneur Winnie Harlow, who together are
Arrowstreet Capital Limited Partnership Boosts Stock Position in Incyte Corporation $INCY
03:21am, Wednesday, 03'rd Dec 2025
Arrowstreet Capital Limited Partnership lifted its position in shares of Incyte Corporation (NASDAQ: INCY) by 701.8% during the second quarter, according to the company in its most recent Form 13F fil
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
02:03pm, Tuesday, 02'nd Dec 2025
Incyte Corporation (INCY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
09:15am, Tuesday, 02'nd Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding.
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel
08:00am, Monday, 01'st Dec 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel.
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue?
12:31pm, Thursday, 27'th Nov 2025
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte: This Profitable Biotech Trades Like A Melting Iceberg
04:09am, Thursday, 27'th Nov 2025
Incyte's Jakafi LOE overhang masked a quietly transforming, profitable biotech whose non‑Jakafi portfolio is now compounding fast enough to support a structural rerating, despite 2028 risks. Q3 2025
